CPSG Home Page
Home Page
About CPSG
Pain Causes
Health News
News Letters
Group Calendar
Guest Book
Web Rings
Awards & Gifts
Acknowledgements

Recommended Reading
Tuesdays with Morrie
by: Albom, Mitch Hardcover


Contact Us Send Email to CPSG

Take the

Site Survey

         Credits         

ZZN Account

dynamicdrive.com

Delphi Forums


 Recommend Us 
To A Friend!
To send our link
Enter email address below:



Hosted Scripts



Click Here!




 If We Don't Have Your Book, Nobody Does.



Subscribe to Enews
Ask the Pain Dr
Book Store
Messages & Chat
Regaining Control
Pain & Rx Resources
Heart Light Candles
Founder's Story


Health News


Celebrex Linked to 10 Deaths

NEW YORK (AP) - 4/20/1999

Monsanto's highly successful painkiller Celebrex has been linked to 10 deaths and 11 cases of gastrointestinal hemorrhages in its first three months on the market, The Wall Street Journal reported today.

Half of the 10 people who died suffered from gastrointestinal bleeding or ulcers, according to reports submitted to the Food and Drug Administration that were obtained by the Journal under the Freedom of Information Act. Two other deaths were attributed to heart attacks, one to drug interaction and one to kidney disorder. No cause of death was given for the 10th fatality.

The Journal did not specify the sources of the so-called adverse event reports, which could come from health professionals, consumers or the drug company itself.

Celebrex, manufactured by St. Louis-based Monsanto Co. (NYSE:MCT - news)'s G.D. Searle & Co. subsidiary, went on the market in January to treat osteoarthritis and rheumatoid arthritis.

Celebrex was touted by Monsanto as an effective pain reliever much like ibuprofen, but was much less likely to cause severe stomach problems such as bleeding ulcers.

So far it has been a gigantic success: 2.5 million prescriptions have been filled in its first 13 weeks on the market, compared with the record 2.7 million prescriptions of anti-impotency drug Viagra filled during its first three months.

Robert DeLap, director of an FDA office of drug evaluation, told the Journal that more research needs to be done before coming to a conclusion about Celebrex's safety. ``Do we think there's a signal that the product poses some special risk? No, not at the moment.''

Searle officials told the Journal they remain excited about Celebrex's performance. ``We really feel the drug is performing as expected. The safety profile is what we would expect,'' said Steve Geis, the company's vice president for arthritis clinical research.

Geis declined to go into details about any cases of death linked to the drug, but said that many patients taking Celebrex have other illnesses and are taking multiple medications.

|| Home || Top of Page || Site Map || Health News Index || Related Links || Guest Book



Take the CPSG Survey

Thank you for visiting the Chronic Pain Support Group. We'd like to know your thoughts, you can take our survey by clicking on the graphic above or leave a message in our guest book.

To visit other pages on our site, click the arrow on the drop down list to select the page you want to view.


The largest cashback shopping reards program on the Internet